Advertisement


Ajay K. Nooka, MBBS, on High-Risk Myeloma: Data on Carfilzomib, Pomalidomide, and Dexamethasone

2023 ASCO Annual Meeting

Advertisement

Ajay K. Nooka, MBBS, of Winship Cancer Center of Emory University, discusses phase II findings showing that, in patients with high-risk myeloma, maintenance therapy with carfilzomib, pomalidomide, and dexamethasone deepened responses. Measurable residual disease negativity was attained in 80% of patients.



Related Videos

Lymphoma

Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses phase II findings from the waveLINE-004 study. It showed that the antibody-drug conjugate zilovertamab vedotin had clinically meaningful antitumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who experienced disease progression after, or have been ineligible for, autologous stem cell transplantation and/or chimeric antigen receptor T-cell therapy (Abstract 7531).

Lung Cancer

Rami Manochakian, MD, on NSCLC: Commentary on the ADAURA Trial of Osimertinib

Rami Manochakian, MD, of Mayo Clinic Florida, offers his perspective on the new phase III findings on osimertinib, a third-generation, central nervous system EGFR tyrosine kinase inhibitor, which demonstrated an unprecedented overall survival benefit for patients with EGFR-mutated, stage IB–IIIA non–small cell lung cancer (NSCLC) after complete tumor resection, with or without adjuvant chemotherapy (Abstract LBA3).

Lymphoma

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on Classical Hodgkin Lymphoma: New Data on Nivolumab, AVD, and Brentuximab Vedotin

Tycel J. Phillips, MD, and Alex F. Herrera, MD, both of the City of Hope National Medical Center, discuss results from the SWOG S1826 study, which showed that nivolumab and AVD (doxorubicin, vinblastine, and dacarbazine) improved progression-free survival vs brentuximab vedotin plus AVD in patients with advanced-stage classical Hodgkin lymphoma. Longer follow-up is needed to assess overall survival and patient-reported outcomes. This trial may be a key step toward harmonizing the pediatric and adult treatment of advanced-stage disease (LBA4).

Kidney Cancer
Immunotherapy

Rana R. McKay, MD, and Brian I. Rini, MD, on Clear Cell RCC: New Data From KEYNOTE-426 on Pembrolizumab Plus Axitinib vs Sunitinib

Rana R. McKay, MD, of the University of California, San Diego, and Brian I. Rini, MD, of Vanderbilt-Ingram Cancer Center, discuss the 5-year follow-up results with the combination of a checkpoint inhibitor plus a VEGFR tyrosine kinase inhibitor as first-line treatment for patients with advanced clear cell renal cell carcinoma (RCC). Pembrolizumab plus axitinib continued to demonstrate improved survival outcomes as well as overall response rate vs sunitinib for patients with previously untreated disease (Abstract LBA4501).

Myelodysplastic Syndromes
Supportive Care

Aaron T. Gerds, MD, on Anemia in Myelofibrosis: New Data on Treatment With Luspatercept

Aaron T. Gerds, MD, of Cleveland Clinic Taussig Cancer Institute, talks about treating the anemia many patients with myelofibrosis experience because of JAK inhibitor therapy. The ACE-536-MF-001 study showed that luspatercept improved anemia and transfusion burden in this population, with a safety profile consistent with that in previous studies (Abstract 7016).

Advertisement

Advertisement




Advertisement